Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.21 Analyst target: $7.60 Upside: 3517.33%
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative diseases. The company is headquartered in Charlottesville, Virginia.
See the full interactive analysis & chart →Informational only — not investment advice.